NEWS

In the early stages, 97% of drug development fails.

In the early stages, 97% of drug development fails. The discovery and development of a new cancer drug is a long, costly, and high-risk process. The estimated time to develop a new cancer drug exceeds 10 years, costs 2 billion EUR or more, and yet only 4% of the new...

CA05 Lead Identification

We have identified insilico, several compounds as inhibitors of CA05, which is a protein kinase overexpressed in various types of tumors with a clear oncogenic role and no type-specific inhibitor, and we have started in vitro trials to select a lead.

Anglonordic

CancerAppy was present at Anglonordic 2022. An event in which we had the opportunity to contact investors and companies in the biotechnology sector and present our research projects.

Tel Aviv – SOSA

We are going to stay in Tel Aviv from March 25th through March 28th looking to learn about entrepreneurship, new relationships and visiting investors.  

4YFN 2022

This week we will be attending the 4YFN in Barcelona as a company selected by @icex and @red.es. Do not hesitate to stop by our stand on Monday and Tuesday. 4YFN 2022 event. Stand 6C37.5

CA04 Antidoby vs Pancreatic cancer

We have begun the development of an antibody (CA04 project) against a specific target validated in pancreatic cancer. 

Icex Next

CancerAppy SL en el marco del Programa ICEX Next, ha contado con el apoyo de ICEX y con la cofinanciación del fondo europeo FEDER. La finalidad de este apoyo es contribuir al desarrollo internacional de la empresa y de su entorno.

CA02/03 Target Identification vs NSCLC

CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies

Total Funding Raised

CancerAppy closed 2021 with €690K total raised.

CA01 Target Identification vs TNBC

Together with our collaborators, we have found a new therapeutic target for TNBCs that we are currently patenting..